CA-XPRIZE
19.4.2021 15:02:16 CEST | Business Wire | Press release
XPRIZE , the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges, today announced that CarbonCure Technologies and CarbonBuilt have won the $20M NRG COSIA Carbon XPRIZE, a prize that set out to convert CO2 emissions into valuable products.
Selected by a panel of independent judges, both winning teams developed solutions aimed at reducing CO2 emissions associated with traditional concrete, which is currently the world’s most abundant human-made material and accounts for seven percent of all global CO2 emissions. The two team’s award-winning technologies will be, and already are, game-changers for global decarbonization and the fight against climate change.
Launched in 2015, the NRG COSIA Carbon XPRIZE was a five-year global competition developed to address rising CO2 emissions by challenging innovators around the world to develop breakthrough technologies that convert the most CO2 into products with the highest net value.
"The NRG COSIA Carbon XPRIZE, its two winners, and the eight other finalists have developed breakthrough technologies that allow humanity to reimagine what is possible for the climate change fight,” said Anousheh Ansari, XPRIZE CEO. “Thanks to the vision laid out and supported by NRG, COSIA and many other partners, flipping CO2 emissions into valuable products is now a proven, successful strategy to build a better world."
The competition included two tracks: the Wyoming track that focused on the conversion of emissions from a nearby coal-fired power plant, the Wyoming Integrated Test Center in Gillette, WY, and the Alberta track which used emissions from an adjacent natural gas-fired plant, the Alberta Carbon Conversion Technology Centre in Calgary, AB. The winning teams, one from each track, converted the most CO2 into products with the highest value, while minimizing their overall CO2 footprint, land use, water use, and energy use.
CarbonCure Technologies, the Alberta track winner from Canada, demonstrated a technology which enabled the production of concrete with a reduced water and carbon footprint without sacrifice to the material’s reliability. Utilizing CarbonCure Technologies’ system, a precise dosage of CO2 is injected into a concrete plant’s reclaimer system, which contains the water used to wash out concrete trucks and mixers. The CO2 is converted to a permanently embedded mineral with strength-enhancing properties which can then be incorporated into new concrete mixes. By reducing the amount of new freshwater, solid waste disposal and cement required, the team, which is backed by Bill Gates’ fund Breakthrough Energy Ventures, Amazon Climate Pledge Fund, BDC Capital and others, is able to reduce the material costs and increase profitability for concrete producers.
“I’m incredibly proud of Team CarbonCure’s hard work, dedication, and ingenuity that contributed to our win. The prize winnings will accelerate our path to achieve our company mission of reducing 500 megatonnes of CO2 emissions annually by 2030,” said Jennifer Wagner, president of CarbonCure and team lead for the competition. “Technology alone will not get us to our net-zero emissions targets — concrete producers, the wider construction community, and policymakers are important allies on our journey to decarbonize the concrete industry.”
The Los Angeles-based Wyoming track winner, UCLA CarbonBuilt, developed technology that reduces the carbon footprint of concrete by more than 50 percent while reducing raw material costs and increasing profitability. The CarbonBuilt concrete formulation significantly decreases the need for ordinary Portland cement while enabling the increased use of low-cost waste materials. During the curing process, CO2 is directly injected from flue gas streams (like power plants or cement factories) into the concrete mixture where it is chemically transformed and permanently stored. Development began at the UCLA Samueli School of Engineering in 2014 with support from the NRG COSIA CARBON XPRIZE, philanthropic foundations, private and corporate sponsors, as well as government agencies including the U.S. Department of Energy.
“I am absolutely thrilled that UCLA CarbonBuilt has won the NRG COSIA Carbon XPRIZE,” said Gaurav N. Sant, professor of civil and environmental engineering and of materials science and engineering at UCLA Samueli. “As a third-generation civil engineer, I have been fascinated with the role that construction has played in solving societal challenges. To have spent the last decade finding a solution to mitigate the carbon footprint of concrete construction with a phenomenal team, and to have won the NRG COSIA Carbon XPRIZE, doing so is an ultimate dream come true,” shared Sant, who is also the director of the UCLA Institute for Carbon Management and founder of CarbonBuilt, Inc., a private company set up to commercialize the pioneering CO2 utilization technology.
“Concrete is one of the world’s most abundant materials, and a crucial frontier in the fight against climate change. The production of Portland cement, the key ingredient that binds concrete and gives it its strength, accounts for approximately seven percent of global CO2 emissions,” says Marcius Extavour, vice president of climate and energy at XPRIZE. “Concrete is also a material that can be readily made using CO2 as an input, which the winning teams have demonstrated really clearly. Now, deploying their technology to avoid and reduce emissions from heavy industry will be a gamechanger for global decarbonization in the fight against climate change.”
Additionally, the USD $20M NRG COSIA Carbon XPRIZE awarded X-Factor awards to Carbon Upcycling-NLT and Carbon Corp, two finalists that created excellent products and compelling demonstrations that deserved recognition. Carbon Upcycling-NLT, based in Calgary, produces nanoparticles with applications in various industries, particularly concrete, construction and plastics. Carbon Corp, who relocated from the USA to Calgary, transforms CO2 into carbon nanotubes, with applications such as lightweight, ultra-strong and cost-effective replacements for metals; stronger cement-composite building materials; and expanding applications in industrial catalysis, batteries, and nanoelectronics.
“Combating climate change is one of the most important challenges we face--requiring us to rethink, reimagine, and embrace new ideas,” said Jeanne-Mey Sun, NRG vice president, sustainability. “Competitions, such as the NRG COSIA Carbon XPRIZE, are opportunities to bring innovators together to develop solutions for the monumental task of decarbonizing our economy. As we recognize today’s winners, we celebrate all of the teams’ hard work and perseverance in this new era in carbon technology.”
“Through COSIA, Canada’s oil sands industry has been proud to support this initiative which has proven that capturing CO2 emissions from natural gas and coal combustion and converting such into usable products can be a game-changer in broader emissions reduction efforts. With breakthrough technologies like these, we can tackle the major causes of climate change while also responsibly meeting global energy demand,” says Wes Jickling, chief executive of COSIA. “As one of many projects underway within COSIA, the competition is a shining example of how innovative cleantech can transform our world. Our hats are off to all the competitors, and we congratulate the winners.”
“Congratulations to XPRIZE winner, CarbonBuilt. The research they’re doing at the Integrated Test Center proves Wyoming is leading the way on carbon capture and utilization,” said U.S. Senator John Barrasso (R-WY). “Last summer, I saw their groundbreaking work firsthand, as they transformed captured carbon dioxide into concrete. CarbonBuilt’s technology will help create new markets and jobs in Wyoming and across the country, while reducing greenhouse gas emissions.”
“Congratulations to CarbonCure who’s already transforming the concrete industry, and to the rest of the contestants in advancing a carbon-tech sector full of opportunity. It has been a privilege for the Alberta Carbon Conversion Technology Centre to host the NRG COSIA Carbon XPRIZE”, says Laura Kilcrease, CEO of Alberta Innovates. “The ACCTC is open for business and we welcome new technology developers to experience the ACCTC as they blaze paths to a net zero future.”
Each grand prize winner will be awarded a USD $7.5 million prize purse and will receive their winnings within 60 days. Those interested in learning more can do so at carbon.xprize.org
About XPRIZE
XPRIZE, a 501(c)(3) nonprofit organization, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million Rainforest XPRIZE, the $10 Million ANA Avatar XPRIZE, the $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling, $5 Million XPRIZE Rapid COVID Testing, and $500K Pandemic Response Challenge. For more information, visit xprize.org.
About NRG
NRG is the leading integrated power company in the U.S., built on the strength of our diverse competitive electric generation portfolio and leading retail electricity platform. A Fortune 500 company, NRG creates value through best in class operations, reliable and efficient electric generation, and a retail platform serving residential and commercial businesses. Working with electricity customers, large and small, we implement sustainable solutions for producing and managing energy, developing smarter energy choices and delivering exceptional service as our retail electricity providers serve almost three million residential and commercial customers throughout the country. More information is available at www.nrg.com . Connect with NRG Energy on Facebook and follow us on Twitter @nrgenergy.
About COSIA
Canada’s Oil Sands Innovation Alliance (COSIA) is a unique alliance of oil sands producers focused on accelerating environmental performance in Canada’s oil sands. COSIA enables collaboration and innovation between big thinkers from industry, government, academia and the wider public to improve measurement, accountability and performance in the oil sands across our environmental priority areas of greenhouse gases, land, water and tailings. COSIA members search the world for solutions to our toughest problems. And we have some of the best minds on the planet working on technologies to enable responsible and sustainable development. To date, COSIA has shared over 1,025 distinct environmental technologies and innovations that cost over $1.6 billion to develop. Visit COSIA at www.cosia.ca . Follow us on LinkedIn , Facebook and Twitter .
About Alberta Innovates
Alberta Innovates is the province’s largest and Canada’s first public research and innovation organization. For a century we have worked closely with the researchers, companies and entrepreneurs who built Alberta’s industries and strengthened communities. Today we are pivoting to the next frontier of opportunity in Alberta and worldwide, driven by emerging technologies across sectors. We provide seed funding, business advice, applied research and technical services, along with avenues for partnership and collaboration. Learn how Alberta Innovates .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005330/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
